Immuno-oncology Therapeutics Market to Reach $3.9 Billion by 2022, Finds Frost & Sullivan

March 29, 2018


Frost & Sullivan’s latest analysis, Immuno-oncology Therapeutics Market—Adoptive T-cell Therapies, Forecast to 2022, finds that the market is expected to generate revenues of $3.9 billion by 2022. Promising clinical trials in artificial T cell receptors (CAR-T) and T-cell receptor (TCR) therapies have inspired significant partnerships worth billions of dollars between large pharmaceuticals, small companies and research institutions. Frost & Sullivan expects medium-to-small-sized companies with innovative immuno-oncology products in development to receive considerable investment income through collaborations. Cell therapy-focused companies will help overcome challenges with this highly specific class of targeted drugs.

For further information on this analysis, please visit: & Sullivan’s recent analysis assesses which adoptive T-cell (CAR-T & TCR) therapies are in development and for which indicators, products launching in the next seven years, key players and their investment activities, cost implications, challenges to development, commercialization of adoptive T-cell therapies, and hurdles payors face relating to the high cost of speciality therapeutics.

“CAR-T therapies are the newest cancer treatments transforming the treatment paradigms of previously difficult-to-treat cancers, with Juno, Gilead and Novartis jockeying for the best-in-class status. Adverse events such as reduced cytokine release syndrome (CRS) as well as decreased vein-to-vein times will contribute to product success. Ongoing research aims to develop allogenic therapies that would replace autologous, patient-specific ones for off-the-shelf therapies from unrelated donors—a treatment accessible to a greater number of patients,” said Barbara Gilmore, Transformational Health Senior Industry Consultant at Frost & Sullivan.

To succeed in a highly competitive environment, Gilmore recommends companies tap into research advances in combination trials targeting more than one pathway to increase response rates over single targeted agents. A combination product produced by one company should be priced more competitively than targeted agents developed and marketed through a competitor’s alliance. 

Four strategic imperatives for growth include:

1. Focusing on identification of cancers with few existing treatments and where immuno-oncology products can better treat patients;

2. Genetically engineered cell therapies providing real-time access to outcomes remission and survival data from in-progress clinical trials, enabling payers and policymakers to determine the potential value of therapies;

3. Partnerships to invest in CAR-T and adoptive T-cell therapies to facilitate the advancements in the treatment of cancers and other diseases with immune cell affect potential; and

4. Investing in supply chain applications related to cryopreservation, lentivirus creation, and allogenic product development to facilitate broader access to this type of therapy.

“Lack of manufacturing infrastructure, high pricing, and undefined reimbursement policies remain notable T-cell therapy hurdles; however, the ultimate goal of increasing overall survival is not insurmountable,” observed Gilmore.

Immuno-oncology Therapeutics Market—Adoptive T-cell Therapies, Forecast to 2022 is part of Frost & Sullivan’s Transformational Health Growth Partnership Services program.



See the latest posts on our homepage


Topic Area: Press Release

Recent Posts
Recent Posts

C. difficile strain evolving to live in hospital rooms

A subset of Clostridium difficile bacteria is on the verge of becoming a new species


Tips for energy efficient healthcare facilities

Improving energy efficiency can be done in a few minutes a day


Security catches woman trying to kidnap toddler from N.Y. hospital

The suspect allegedly took a stroller with a two-year-old inside and fled St. Joseph’s Hospital


Rhode Island hospital employees to get panic buttons

Contract with Our Lady of Fatima Hospital addresses concerns around safety


Maintaining sidewalks and parking garages requires a comprehensive, strategic approach

By developing inspection guidelines for common causes of problems, managers can extend the performance life of concrete components


Post Comment


News & Updates • Webcast Alerts • Building Technologies

All fields are required.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.